173 related articles for article (PubMed ID: 27184943)
1. Acute and Late Genitourinary Toxicity after 72 Gy of Conventionally Fractionated Conformal Radiotherapy for Localised Prostate Cancer: Impact of Individual and Clinical Parameters.
Stankovic V; Džamic Z; Pekmezovic T; Tepavcevic DK; Dozic M; Saric M; Vuckovic S; Nikitovic M
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):577-86. PubMed ID: 27184943
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of the lower gastrointestinal tract and its predictive factors after 72Gy conventionally fractionated 3D conformal radiotherapy of localized prostate cancer.
Stankovic V; Nikitovic M; Pekmezovic T; Pekmezovic D; Kisic Tepavcevic D; Stefanovic Djuric A; Saric M
J BUON; 2016; 21(5):1224-1232. PubMed ID: 27837627
[TBL] [Abstract][Full Text] [Related]
3. Diabetes mellitus: a predictor for late radiation morbidity.
Herold DM; Hanlon AL; Hanks GE
Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):475-9. PubMed ID: 10078625
[TBL] [Abstract][Full Text] [Related]
4. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.
Dolezel M; Odrazka K; Vaculikova M; Vanasek J; Sefrova J; Paluska P; Zouhar M; Jansa J; Macingova Z; Jarosova L; Brodak M; Moravek P; Hartmann I
Strahlenther Onkol; 2010 Apr; 186(4):197-202. PubMed ID: 20354663
[TBL] [Abstract][Full Text] [Related]
6. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
[TBL] [Abstract][Full Text] [Related]
7. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
8. Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):397-405. PubMed ID: 15890581
[TBL] [Abstract][Full Text] [Related]
9. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12.
Coen JJ; Bae K; Zietman AL; Patel B; Shipley WU; Slater JD; Rossi CJ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1005-9. PubMed ID: 20932675
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
11. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.
Karlsdóttir A; Muren LP; Wentzel-Larsen T; Dahl O
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1478-86. PubMed ID: 18060703
[TBL] [Abstract][Full Text] [Related]
12. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.
Michalski JM; Bae K; Roach M; Markoe AM; Sandler HM; Ryu J; Parliament MB; Straube W; Valicenti RK; Cox JD
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):14-22. PubMed ID: 19577865
[TBL] [Abstract][Full Text] [Related]
13. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate.
Schultheiss TE; Hanks GE; Hunt MA; Lee WR
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):643-9. PubMed ID: 7790250
[TBL] [Abstract][Full Text] [Related]
14. Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.
Thor M; Deasy JO; Paulus R; Robert Lee W; Amin MB; Bruner DW; Low DA; Shah AB; Malone SC; Michalski JM; Dayes IS; Seaward SA; Gore EM; Albert M; Pisansky TM; Faria SL; Chen Y; Koontz BF; Swanson GP; Pugh SL; Sandler HM
Radiother Oncol; 2019 Jun; 135():19-24. PubMed ID: 31015166
[TBL] [Abstract][Full Text] [Related]
15. A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.
Shimizuguchi T; Nihei K; Okano T; Machitori Y; Ito K; Karasawa K
Int J Clin Oncol; 2017 Apr; 22(2):373-379. PubMed ID: 27778117
[TBL] [Abstract][Full Text] [Related]
16. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
[TBL] [Abstract][Full Text] [Related]
17. Acute and late genitourinary toxicity of conformal radiotherapy for prostate cancer.
Yoshimura R; Iwata M; Shibuya H; Sakai Y; Kihara K
Radiat Med; 2006 Oct; 24(8):553-9. PubMed ID: 17041791
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
20. Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes.
Zimmermann M; Taussky D; Menkarios C; Vigneault É; Beauchemin MC; Bahary JP; Martin AA; Diaz de Bedoya LV; Lambert C
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):386-92. PubMed ID: 26782838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]